Altimmune Stock Valuation

ALT
 Stock
  

USD 10.35  0.12  1.17%   

What would the acquisition value of Altimmune be today? Calculating the true value of any business is not as easy as it may seem. While the market cap of a public entity, such as Altimmune, is its stock price multiplied by the total number of shares outstanding, calculating Altimmune's enterprise value requires a different approach. It uses Altimmune's balance sheet items such as long-term debt, the book value of the preferred stock, minority interest, and other important financials.
Tangible Asset Value is likely to gain to about 222.7 M in 2022, whereas Free Cash Flow is likely to drop (92.7 M) in 2022.
Altimmune shows a prevailing Real Value of $15.13 per share. The current price of the firm is $10.35. At this time, the firm appears to be undervalued. Our model approximates the value of Altimmune from analyzing the firm fundamentals such as Shares Outstanding of 49.16 M, operating margin of (25.94) %, and Return On Equity of (0.42) % as well as examining its technical indicators and Probability Of Bankruptcy. In general, we favor acquiring undervalued instruments and selling overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
  
Altimmune Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as Altimmune's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.

Altimmune Most Recent Valuation Data

Beta
0.3966
Change Receivables
4.2 M
Fiscal Year End
December
Property Plant And Equipment Net
1.4 M
Enterprise Value
353.9 M
Net Debt
-190.3 M
Undervalued
Today 10.35
Please note that Altimmune's price fluctuation is somewhat reliable at this time. Calculation of the real value of Altimmune is based on 3 months time horizon. Increasing Altimmune's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Altimmune is useful when determining the fair value of the Altimmune stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Altimmune. Since Altimmune is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Altimmune Stock. However, Altimmune's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
15.13
Real Value
21.19
Upside
Estimating the potential upside or downside of Altimmune helps investors to forecast how Altimmune stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Altimmune more accurately as focusing exclusively on Altimmune's fundamentals will not take into account other important factors:
Earnings
Estimates (4)
LowProjected EPSHigh
-2.48-2.18-1.85
Details
Hype
Prediction
LowEstimated ValueHigh
4.3410.4016.46
Details
Naive
Forecast
LowNext ValueHigh
6.2412.3018.35
Details
6 Analysts
Consensus
LowTarget PriceHigh
25.0030.5036.00
Details
Traditionally analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Altimmune's intrinsic value based on its ongoing forecasts of Altimmune's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Altimmune's closest peers. When choosing an evaluation method for Altimmune, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using both methods to arrive at a better estimate.

Altimmune Investments

97.66 Million

Altimmune Valuation Drivers Correlation

Many accounts on the financial statements of Altimmune are highly interrelated and sometimes correlated. Consequently, when conducting Altimmune's valuation analysis, one should examine all of the accounts reported to obtain a complete picture of its financial situation. We provide a unique feature to present a conventional correlation table purposely composed against different valuation-related drivers of Altimmune
Click cells to compare fundamentals

Altimmune Valuation Trend

Knowing Altimmune's actual value is paramount for traders to make sound investment determinations. Altimmune's real value is not only important for the investor to make better decisions but also for a more accurate overall view of Altimmune's financial worth over time since having this information enables investors and analysts to forecast the earnings more efficiently. Using both Altimmune's enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing descisions.

Altimmune Market Cap

Altimmune is number one stock in market capitalization category among related companies. Market capitalization of Health Care industry is presently estimated at about 321.74 Billion. Altimmune adds roughly 518.63 Million in market capitalization claiming only tiny portion of equities under Health Care industry.
Capitalization  Workforce  Valuation  Revenue  Total debt

Altimmune Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining Altimmune's current stock value. Our valuation model uses many indicators to compare Altimmune value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Altimmune competition to find correlations between indicators driving Altimmune's intrinsic value. More Info.
Altimmune is number one stock in equity positions weight category among related companies. It is number one stock in year to date return category among related companies creating about  0.08  of Year to Date Return per Equity Positions Weight. The ratio of Equity Positions Weight to Year to Date Return for Altimmune is roughly  12.92 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Altimmune by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Altimmune's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Altimmune's earnings, one of the primary drivers of an investment's value.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Altimmune's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Altimmune and how it compares across the competition.

About Altimmune Valuation

The stock valuation mechanism determines the current worth of Altimmune on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Altimmune. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Altimmune based exclusively on its fundamental and basic technical indicators. By analyzing Altimmune's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Altimmune's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Altimmune. We calculate exposure to Altimmune's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Altimmune's related companies.
Fiscal Year End
December
Industry
Biotechnology
Concentration
Biotechnology
Full Time Employees
47
Service Category
Biotechnology
Employer Id Number
20-2726770
Last ReportedProjected for 2022
Gross Profit4.4 M4.5 M
Profit Margin(37.19) (40.13) 

Altimmune Current Valuation Indicators

Valuation refers to the process of determining the present value of Altimmune and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Altimmune we look at many different elements of the entity such as Altimmune's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation. Altimmune's valuation analysis is also a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Altimmune's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Altimmune, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Altimmune's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Altimmune's worth.
Please continue to Trending Equities. You can also try Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Complementary Tools for analysis

When running Altimmune price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Is Altimmune's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Altimmune. If investors know Altimmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Altimmune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
518.6 M
Quarterly Revenue Growth YOY
(0.99) 
Return On Assets
(0.23) 
Return On Equity
(0.42) 
The market value of Altimmune is measured differently than its book value, which is the value of Altimmune that is recorded on the company's balance sheet. Investors also form their own opinion of Altimmune's value that differs from its market value or its book value, called intrinsic value, which is Altimmune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Altimmune's market value can be influenced by many factors that don't directly affect Altimmune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Altimmune's value and its price as these two are different measures arrived at by different means. Investors typically determine Altimmune value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Altimmune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.